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ABSTRACT Preimplantation embryos utilize
mitogen-activated protein kinase signaling (MAPK)
pathways to relay signals from the external environ-
ment to prepare appropriate responses and adapta-
tions to a changing milieu. It is therefore important to
investigate how MAPK pathways are regulated during
preimplantation development. This study was con-
ducted to investigate whether PP2Cd (Ppm1d, WIP1)
is expressed during mouse preimplantation develop-
ment and to determine the influences of p38 MAPK
inhibition on expression of Trp53 (p53), Ppm1d,
(WIP1), and Cdkn2a (p16) during mouse preimplan-
tation development. Our results indicate that Trp53,
Ppm1d, and Cdkn2a mRNAs and TRP53 and PP2Cd
proteins are expressed throughout mouse preimplanta-
tion development. Treatment of 2-cell embryos with
SB220025 (potent inhibitor of p38 MAPK a/b/MAPK
14/11) significantly increased Trp53, Ppm1d and
Cdkn2a and Mapk14 mRNA levels at 12 and 24 hr.
Treatment of 8-cell embryos with SB220025 for 12 hr
increased Trp53, Ppm1d, and Cdkn2a mRNA levels,
but not Mapk14 mRNA levels. Treatment of 8-cell
embryos for 24 hr increased Trp53, and Ppm1d
mRNA levels, but decreased Cdkn2a and Mapk14
mRNA levels. Therefore, blockade of p38 MAPK
activity is associated with embryo stage specific
influences on Trp53, Ppm1d, Cdkn2a, and Mapk14
expression during mouse preimplantation develop-
ment. These results define downstream targets of
p38 MAPK during preimplantation development and
indicate that the p38 MAPK pathway regulates Trp53,
Ppm1d, and Cdkn2a expression. This study increases
our understanding of the mechanisms controlling
preimplantation development and of the interactions
between preimplantation embryos and their culture
environments. Mol. Reprod. Dev. 74: 821–834,
2007.  2007 Wiley-Liss, Inc.
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INTRODUCTION
Preimplantation development is susceptible to mod-
ification by exposure to variations in the external
environment (Rinaudo and Schultz, 2004; Johnson,
2005). The consequences of environmental insults range
from modification of embryonic gene expression pat-
terns, to impaired embryohealth, fetal development and
greater susceptibility to disease later in life (Rinaudo
and Schultz, 2004; Johnson, 2005). Research is now
focused on understanding the mechanisms upon which
the external environment may affect the embryonic
developmental program. This research has revealed
that mitogen-activated protein kinase (MAPK) signal-
ingpathwaysare importantmediators of environmental
stresses on embryonic gene expression anddevelopment
(Saba-El-Leil et al., 2003; Natale et al., 2004; Maekawa
et al., 2005; Paliga et al., 2005; Wang et al., 2005).
The MAPK signal transduction pathways are well-
characterized networks that regulate cellular processes
including gene transcription, protein synthesis, cell
cycle, apoptosis, cell differentiation, inflammation, and
cytoskeletal rearrangements (Herskowitz, 1995; Mar-
shall, 1995; Kyriakis and Avruch, 1996; Ono and Han,
2000; Kyriakis andAvruch, 2001). In general, allMAPK
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signaling pathways include a central three-tiered
signaling module consisting of MAPKs, MAPK kinases
(MAP2Ks) andMAPKkinasekinases (MAP3Ks).MAPK
core signalingmodules are regulatedbyawide variety of
upstream activators and inhibitors (Herskowitz, 1995;
Marshall, 1995; Kyriakis and Avruch, 1996, 2001; Ono
and Han, 2000).
Our studies have focused upon defining the role and
regulation of the p38 MAPK pathway during preim-
plantation development (Natale et al., 2004; Madan
et al., 2005; Paliga et al., 2005). p38MAPKwas initially
identified by its ability to specifically bind pyridinyl
imidazole derivatives (i.e., cytokine suppressive anti-
inflammatory drugs; CSAIDS), which inhibit the pro-
duction of pro-inflammatory cytokines (Lee et al., 1994).
To date, four p38 MAPK members, encoded by distinct
genes, have been cloned and characterized: p38a
(MAPK14) (Han et al., 1994; Lee et al., 1994), p38b
(MAPK11) (Jiang et al., 1997), p38g (MAPK12) (Lechner
et al., 1996; Cuenda et al., 1997), and p38d (MAPK13)
(Jiang et al., 1997). p38 MAPKs are activated by
MAP2Ks including MAP2K3 (MKK3), MAP2K6 (MKK6),
and MAP2K4 (MKK4) (Keesler et al., 1998; Ono and
Han, 2000). The MAP3Ks upstream of the MAP2K/p38
MAPK pathway are even more expansive and include
the mitogen-activated protein/extracellular signal-
regulated kinase kinase kinases (MEKKKs/MAP3K1-
5), the mixed lineage kinases (MLKs/MAP3K9-11) and
the thousand and one kinases (TAOKs, MAP3K17)
(Kyriakis and Avruch, 2001). A number of p38 MAPK
substrates have been identified and include MAPK-
activated protein kinase-2 (MAPKAPK2), MAPKAPK3,
and p38 regulated and activated kinase (PRAK, MAP-
KAPK5). Once activated, MAPKAPK2, MAPKAPK3,
andPRAKphosphorylateheat shockprotein27 (HSP27)
(McLaughlin et al., 1996; Sithanandam et al., 1996;
Huot et al., 1997; New et al., 1998; Lambert et al., 1999)
which regulates the actin cytoskeleton (Huot et al.,
1997; Lambert et al., 1999). p38 MAPK also enters the
nucleus to phosphorylate transcription factors includ-
ing activator protein 1 (AP1, JUN), CREB homologous
protein (CHOP, DDIT3), and activating transcription
factor 2 (ATF2) (Habener, 1990; Ono and Han, 2000;
Kyriakis and Avruch, 2001).
In addition, p38 MAPK phosphorylates the tumor
suppressor protein, TRP53 (p53) (Bulavin et al., 1999;
Sanchez-Prieto et al., 2000; She et al., 2000; Kishi et al.,
2001).Trp53 transcripts are present throughoutmurine
preimplantation development, and are increased in
1-cell stage embryos exhibiting programmed cell death
(PCD) (Jurisicova et al., 1998). Recently it was deter-
mined that TRP53 is a key component of a p38 MAPK
regulatory feedback loop (Takekawa et al., 2000). In
response to UV radiation, osmotic stress, and che-
motherapeutic agents, p38 MAPKs directly phosphor-
ylate TRP53 (Bulavin et al., 1999; Sanchez-Prieto et al.,
2000; She et al., 2000; Kishi et al., 2001). Active TRP53
induces the transcription of the wild-type p53-induced
phosphatase 1, Wip1 (PP2Cd or Ppm1d). PP2Cd is a
member of the type 2C protein phosphatase (PP2C)
family (Fiscella et al., 1997). PP2Cs are implicated in
stress protection, sexual differentiation, and cell-cycle
control (Schweighofer et al., 2004). Ppm1d-null mouse
embryonic fibroblasts (MEFs) display elevated TRP53
activity and its downstream targets, but also express
higher levels of CDKN2A (p16-INK4A), an inhibitor of
the cyclinDprotein kinases,which are in turnupstream
regulators of the retinoblastoma (Rb) tumor-suppressor
protein (Bulavin et al., 1999, 2004). Thus, deletion of
Ppm1d activated two distinct tumor suppressors, the
TRP53 and CDKN2A/CDKN2D pathways. PP2Cd con-
tributes to the TRP53-p38 MAPK-PP2Cd regulatory
circuit by dephosphorylating p38 MAPK at threonine
180 and thus inhibiting p38 MAPK activity (Takekawa
et al., 2000).
All principle members of the p38 MAPK family are
expressed throughout preimplantation development
(Natale et al., 2004; Madan et al., 2005). Inhibition
of MAPK 14/11 activity using CSAIDs, results in a
reversible arrest of preimplantation development at
the 8–16 cell stage that is accompanied by a loss of
filamentous actin, decreased HSP25/27 phosphorylated
protein, and redistribution of a-catenin (Natale et al.,
2004; Paliga et al., 2005). We have very recently
discovered that p38MAPKactivity during preimplanta-
tion development is regulated by culture medium
osmolarity and that p38 MAPK activation is associated
with increased levels of Osmosensing Scaffold for
MEKK3 (OSM) or CCM2which is an osmotic responsive
scaffolding protein that mediates the assembly of
RhoGTPases, MAP3K, MAP2K, and p38 MAPK into
phospho-relay modules to regulate actin cytoskeletal
events (Uhlik et al., 2003). The present study is focused
on investigating the expression and regulation ofTrp53,
Ppm1d, and Cdkn2a during preimplantation develop-
ment (Bulavin et al., 1999; Sanchez-Prieto et al., 2000;
Takekawa et al., 2000; Bulavin et al., 2004). Determina-
tion of the effects of p38 MAPK inhibition on their
expression during early development will contribute
to an understanding of p38 MAPK regulation during
this developmental period and also provides a possible
mechanism for the modulation of environmental influ-
ences on embryo development. We have discovered that
Trp53, Ppm1d, and Cdkn2a mRNAs and TRP53 and
PP2Cd proteins are expressed during preimplantation
development and that blockade of p38 MAPK activity is
associated with embryo stage specific influences on
Trp53,Ppm1d,Cdkn2a, andMapk14 expression during
mouse preimplantation development.
MATERIALS AND METHODS
Materials
SB220025 and SB202474 were purchased from Cal-
biochem (La Jolla, CA). Both compounds were dissolved
in dimethylsulphoxide (DMSO) to make stock concen-
trations of 10mMandwere stored at208C.The embryo
culture medium, potassium simplex optimized media
with amino acids (KSOMaa), was purchased from
Chemicon (Temecula, CA). All real-time reverse tran-
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scription polymerase chain reaction (RT-PCR) reagents
were purchased from Applied Biosystems (Foster City,
CA).
Superovulation and Mouse Embryo Collection
FemaleMF-1 or CD-1mice (Harlan, Indianapolis, IN;
Charles River, PQ) were injected with 5 IU pregnant
mare’s serum gonadotropin (PMSG; Intervet, Whitby,
ON, Canada) followed by 5 IU human chorionic
gonadotropin (hCG; Sigma, St. Louis, MO) 48 hr later.
Female mice were then mated with CD-1 males.
Successful mating was determined by the presence of a
vaginal plug the next morning. Embryos were collected
at specified times following hCG injection, which
correspond toappropriate cleavage stages: 1-cell zygotes
24 hr post-hCG; 2-cell, 48 hr; 4-cell, 60 hr; 8-cell, 65–
68hr;morulae, 80–85hr and blastocyst, 90 hr. Embryos
at the 1-cell throughmorula stagewere flushed from the
oviducts and uteri of female mice using flushingmedia I
(Spindle, 1980). Blastocysts were flushed from the uteri
using flushing media II (Spindle, 1980). Embryos were
washed several times in flushing medium and collected
in pools to be either: (1) frozen and stored at 808C
for RNA extraction; (2) fixed for immunofluorescence
analysis of protein distribution; or (3) cultured in 20 ml
drops of EmbryoMax1 KSOMaa (potassium simplex
optimized medium with amino acids) Liquid Mouse
Embryo Media (Chemicon International—Specialty
Media, Temecula, CA) (Ho et al., 1995) under mineral
oil and maintained in culture under 5% CO2 in air
atmosphere at 378C. Animal care and treatment
followed protocols established by theUWOAnimal Care
Committee.
RNA Extraction and Reverse Transcription
Total RNA was extracted from 40 mg pieces of adult
mouse liver tissue using TRI Reagent (Molecular
Research Center, Cincinnati, OH). RT reactions were
performedusing oligo(dT)12–18 primers andSuperScript
II reverse transcriptase (Invitrogen, Burlington, ON,
Canada) as previously described (Offenberg et al., 2000;
Natale et al., 2004). For embryos, 0.025 pg of luciferase
RNA (Promega Corporation, Madison, WI) per embryo
was added to pools of 20 (for experimental treatment
trials) or 40 (for developmental series, 1-cell to blas-
tocyst stage) embryos and total RNA was extracted
using TRI Reagent and Poly Acryl Carrier (Molecular
Research Center). The Sensiscript RT Kit and protocol
from Qiagen was employed to reverse transcribe RNA
extracted from these embryos.
PCR Primer Sets
Primer sets were designed and synthesized for mouse
Trp53, Ppm1d, and Cdkn2a (Table 1). The web-based
program Primer 3 release 1.0 (Whitehead Institute for
Biomedical Research, Cambridge,MA,www.http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) was used
to generate primer pairs based on available mouse
nucleotide sequences in GenBank databases and were
generated by Sigma Genosys, Oakville, ON, Canada.
The optimal PCR conditions for all primers were char-
acterized in adult mouse liver tissue cDNA samples by
running samples at various Mg2þ concentrations and
annealing temperatures. The RT-PCR products ampli-
fied from adult liver tissue cDNA and blastocyst cDNA
were purified using a QIAquick Gel Extraction Kit
(Qiagen, Maryland). Purified cDNA was then sub-
mitted for nucleotide sequencing (DNA Sequencing
Facility, Robarts Research Institute, London, ON,
Canada). To confirm the identity of each PCR product,
an NCBI BLAST search was then carried out on each
nucleotide sequence to compare it to sequences avail-
able in the GenBank nucleotide sequence databases.
Qualitative RT-PCR Amplification
Standard PCR was applied as previously described
(Offenberg et al., 2000; Natale et al., 2004), using a total
amount of cDNA equal to one to two embryos per
reaction, or approximately 200 pg adult mouse liver
RNA.PCRreactionswere carried out ina volumeof 50ml
consisting of 0.2UofPlatinumTaq (Invitrogen), 1PCR
Platinum Buffer (Invitrogen), 2 mM MgCl2, 0.2 mM of
each dNTP, and 1.0 mM of each PCR primer (Table 1)
usingagradient thermocycler (Techne,Burlington,NJ).
Platinum Taq was activated by an initial incubation at
958C for 5 min followed by a series of up to 45 cycles
consisting of denaturation at 958C for 50 sec, reanneal-
ing primers to target sequence at 56–648C for 50 sec and
primer extensions at 728C for 50 sec. The amplification
cycles concluded with a 10 min final extension at 728C.
Molecular Reproduction and Development. DOI 10.1002/mrd
TABLE 1. Nucleotide Sequences of Primer Sets Used for Qualitative Polymerase
Chain Reaction Amplification (PCR) of Trp53, Ppm1d, Cdkn2a, and Luciferase
cDNAs
Gene product Primer Primer sequence
Product
size (bp)
GenBank accession
number
Trp53 50 AGAAAATTTCCGCAAAAAGGA 450 NM_011640
30 GCTGAGCCCTAGCTACAAGGT
Ppm1d 50 AAGAAGCAGAAAGGCTTCACC 445 NM_016910
30 TTGCTACAGCCAGAAAAGGAA
Cdkn2a 50 TGATGATGATGGGCAACG 248 NM_009877
30 ACGGGAACGCAAATATCG
Luciferase 50 TTGACAAGGATGGATGGCTAC 395 Sequence provided
by Promega
30 TTCGGTACTTCGTCCACAAAC
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PCR products were resolved on a 2.0% agarose gel with
1.0 mg/ml ethidium bromide (Invitrogen). PCR reactions
were repeated a minimum of three times using cDNA
prepared from embryos at each of the indicated stages
and isolated from a minimum of three separate devel-
opmental series. Positive (tissue cDNA: liver) and
negative control (no cDNA template) samples were
included for each primer set in every experiment.
Quantitative Real-Time PCR Amplification
Real-time RT-PCR was performed using the ABI
PRISM 7900HT sequence detection system (Applied
Biosystems). Predesigned and qualified TaqMan1Gene
Expression Assays for the genes of interest Trp53,
Ppm1d, Cdkn2a, andMapk14, were employed (Applied
Biosystems) (Jeong et al., 2005). The probe sequence for
luciferase was directed against a target site 550 bp into
the full-length sequence used to generate the Luciferase
Control RNA (Promega Corporation). The target site
specifies an approximate location for generation of a
TaqMan1 probe, and each target site was verified to be
unique by performing BLAST1 analysis. Dual-labeled
probes were synthesized (Applied Biosystems) to con-
tain the reporter dye 6-carboxyfluorescein (6-FAM) at
the 50 end and a nonfluorescent quencher dye at the 30
end. A list of assay ID’s and accession numbers of the
target sequences used to design the primer-probes sets
are shown in Table 2. PCRswere carried out in a 96-well
plate in a 50 ml reaction containing 25 ml TaqMan1
Universal PCR Master Mix (2 concentration solution
optimized for TaqMan1 reactions and contains Ampli-
Taq Gold DNA Polymerase, AmpErase UNG, dNTPs
with UTP, Passive Reference, and optimized buffer
components), 2.5 ml of 20 TaqMan1 Gene Expression
Assay Mix (unlabeled PCR primers and FAM dye-
labeled TaqMan MGB probe), 10 ml of appropriate
dilution of cDNA (0.1 embryo/ml), and 10 ml of water.
Amplification conditions were 2 min at 508C (UNG
activation), 5min at 958C, 60 cycles of 15 sec at 958Cand
60 sec at 608C.Each reactionwas run in triplicate on the
plate, and three developmental series and three experi-
mental replications were completed. All three genes of
interest were validated against the exogenous control to
ensure equal amplification efficiency.
Final quantification was conducted using the com-
parative CT method (Leutenegger et al., 2000). Within
the log-linear phase of the amplification curve, the
difference between each cycle was equivalent to a
doubling of the amplified product of the PCR. The DCT
value was determined by subtracting the luciferase CT
value for each sample from the target gene CT value of
the sample. Calculation ofDDCT used either the 1-cell or
DMSO cultured sample DCT value as a constant to
subtract fromall otherDCTsamplevalues. Fold-changes
in the relativemRNA expression of the target genewere
determined using the formula 2DDCT.
Antisera
We employed TRP53-phospho which is a mouse
antiserum raised against a synthetic phospho-peptide
corresponding to residues surrounding Ser15 of human
TRP53 (Cell Signaling, Danvers,MA). PP2Cd is a rabbit
antiserumraisedagainst aminoacids 306–605mapping
at the C-terminus of human PP2Cd (Santa Cruz
Biotechnology, Santa Cruz, CA). Both primary anti-
bodies were tested over a range of concentrations and
were most effective at a dilution of 1:100 from the
commercial stock concentration. Primary antibodies
were labeled using fluorescein isothiocyanate-conju-
gated (FITC)-donkey anti-mouse secondary antiserum,
for TRP53-phospho, or FITC-donkey anti-rabbit second-
ary antiserum for PP2Cd 1 (Jackson Immuno Labs, La
Jolla, MA).
Whole-Mount Indirect Immunofluorescence
Localization of TRP53-phospho and PP2Cd in pre-
implantation stage mouse embryos (1-, 2-, 4-, 8-cell,
morula, and blastocyst) was assessed by whole-mount
indirect immunofluorescence methods combined with
observation using a laser scanning confocal microscope.
Themethodwas applied to aminimumof three replicate
embryo developmental series representing a minimum
of 10 embryos for each stage per replicate. Negative
controls were also conducted in which embryos were
exposed to the sameprocedure in the absence of primary
antibody to assess the levels of background and
nonspecific binding of secondary antibody. After collec-
tion, embryoswere fixed in 2% paraformaldehyde (PFA)
in PBS for 20 min at room temperature. Following
fixation, embryoswere processed for immediate applica-
tion of immunofluorescence methods or were stored at
48C in 1 PBS þ0.09% sodium azide (Embryo Storage
Buffer) for a maximum of 2 weeks. For immunofluores-
cence, fixed embryos were permeabilized and blocked in
1 PBS þ5% donkey serum þ0.01% Triton X-100 for
1 hr at room temperature. Embryos were washed in 1
PBS and incubatedwith primary antibody diluted 1:100
in 1 PBS þ0.5% donkey serum þ0.005% Triton X-100
Molecular Reproduction and Development. DOI 10.1002/mrd
TABLE 2. Assay ID’s and Accession Numbers for Real-Time Polymerase Chain
Reaction (PCR) Primer Sets Used to Amplify Trp53, Ppm1d, Cdkn2a, Mapk14, and
Luciferase cDNAs
Gene product Applied biosystems assay ID GenBank accession number
Trp53 Mm00441964_g1 NM_011640
Ppm1d Mm00450393_m1 NM_016910
Cdkn2a Mm00494449_m1 NM_009877
Mapk14 Mm00442497_m1 NM_011951.1
Luciferase Custom-made primer/probe set Sequence provided by Promega
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for 1hr at 378C, followedby three 30minwashes at 378C.
Primary antibodies were detected following incubation
for 1 hr in FITC-conjugated secondary antibodies
diluted to 1:200. To visualize F-actin localization and
to stain nuclear DNA, the first 30 min wash following
secondary antibody incubation included rhodamine-
conjugated phalloidin (Sigma-Aldrich Canada Ltd.,
Oakville, ON, Canada), diluted to 1:200 from 5 mg/ml
stock solution, and DAPI (Sigma-Aldrich Canada Ltd.),
diluted to 1:2,000 from 1mg/ml stock solution. Embryos
were thensubjected to threeadditional 30minwashesat
378C. Embryos were finally mounted in Fluro-Guard
Antifade Mounting Reagent (BioRad, Mississauga, ON,
Canada). Fluorescence patterns were examined by
confocal microscopy using a Zeiss LSM 510 (laser
scanning microscope) based on an inverted Axiovert
100 microscope using a Zeiss 40 water Plan Apochro-
mat objective lens with a numerical aperture of 1.2. The
confocal microscope used cooled photomultiplier tubes
produced by Hamamatsu (PMT). The images were then
captured and stored as TIFF files by the Zeiss LSM
software package. To capture confocal images, satura-
tion levels were optimized using control embryos and all
subsequent embryos were scored using absorbance
levels established form control exposures.
Assessment OF Trp53, Ppm1d, Cdkn2a, and
Mapk14 mRNA Levels Following p38
MAPK Inhibition
Embryos were flushed from oviducts of timed-preg-
nantmice at the 2-cell (48 hr post-hCG) and 8-cell stages
(72 hr hCG) as described (Natale et al., 2004; Paliga
et al., 2005). Groups of 20 embryos eachwere pooled and
washed. Groups were cultured for 12 or 24 hr in either a
20 ml drop of KSOMaa plus 0.1% DMSO, KSOMaa plus
10 mMSB220025 (CSAID, activeMAPK14/11 inhibitor),
or KSOMaa plus 10 mM SB272474 (CSAID, inactive
analog) (Natale et al., 2004; Paliga et al., 2005).
Following each treatment period, embryos were plac-
ed in 500 ml TRI-Reagent, frozen in liquid nitrogen and
stored at 808C until processed for RNA extraction and
application of real-time RT-PCR analysis of transcript
abundance. Three experimental replicates were con-
ducted for each set of embryo stages.
Statistical Analysis
Statistical analysis of data were carried out using
SPSS 14.0 (SPSS, Inc., Chicago, IL) software package.
Data showed normal distribution and one-way ANOVA
was used to determine treatment effects followed by
Tukey’s Multiple Comparison Test to determine statis-
tical significance. Differences of P 0.05 were consid-
ered significant.
RESULTS
Detection of Trp53, Ppm1d, and Cdkn2a
Transcripts in Mouse Preimplantation Embryos
The application of qualitative RT-PCR methods to
embryo cDNA samples resulted in the detection of
Trp53, Ppm1d, and Cdkn2a transcripts throughout
mouse preimplantation development (Fig. 1A). The
RT-PCR products amplified from adult liver tissue
cDNAandblastocyst cDNAwerepurifiedandsequenced
to confirm the identities of each RT-PCR product. The
Trp53 and Cdkn2a mouse embryo RT-PCR products
displayed 99% sequence identity to their respective
GenBank mouse nucleotide sequences. The Ppm1d
embryo RT-PCR product displayed a 100% sequence
identity to its GenBank mouse nucleotide sequence.
After determining that Trp53, Ppm1d, and Cdkn2a
mRNAs were present during preimplantation develop-
ment, we next assessed the variations in their relative
abundance throughout preimplantation development
by applying real-time RT-PCR methods. Fold-changes
in the relative mRNA levels of the target genes were
determined using the formula 2DDCT as described.
Trp53mRNA levels displayed an accumulation pattern
where they were elevated at the 1-cell stage, then
dropped significantly (P0.05) by the 2-cell stage to
reach 16% of the 1-cell levels (Fig. 1B). Trp53 transcript
levels remained low until the morula stage when they
increased to reach a level that was 23% higher than 1-
cell levels (Fig. 1B). The Trp53, mRNA levels at the
blastocyst stage increased to become 176% of the levels
observed at the 1-cell stage (Fig. 1B). In contrast to the
accumulation pattern displayed by Trp53 mRNAs,
Ppm1d, and Cdkn2a mRNA levels were highest at the
1-cell stage, dropped precipitously at the 2-cell stage
(16 and 4% of 1-cell levels, respectively) and remained
low but detectable through to the blastocyst stage
(Fig. 1C,D, respectively). Small but significant varia-
tions (P 0.05) were observed for both gene transcripts
between the 2-cell and blastocyst stages. Ppm1d
transcript levels dropped significantly to reach 3% of
the 1-cell levels at the 8-cell stage and then rose again at
the morula stage to become 13% of the 1-cell levels
(Fig. 1C). Cdkn2a mRNAs rose at the 8-cell stage to
reach 20% of the 1-cell levels, and then decreased to
become 9 and 11% of the 1-cell levels at the morula and
blastocyst stages, respectively (Fig. 1D).
Distribution of TRP53 AND PP2Cd Polypeptides
Throughout Preimplantation Development
The protein distribution patterns of TRP53-phospho
and PP2Cd were examined using whole-mount indirect
immunofluorescence applied to three independent
developmental series of embryos (1-, 2-, 4-, 8-cell,morula
and blastocyst). TRP53-phospho protein was detect-
ed throughout mouse preimplantation development
(Fig. 2A–G). TRP53-phospho immunofluorescence was
predominantly cytoplasmic, however nuclear fluores-
cence was also observed (but not in all blastomeres)
beginning at the 4-cell stage and continuing onto the
blastocyst stage (Fig. 2C–F). TRP53-phospho immuno-
fluorescence was detected in both trophectoderm and
inner cell mass cell lineages. PP2Cd protein was also
detected throughout mouse preimplantation develop-
ment (Fig. 2H–N). PP2Cd immunofluoresence was pre-
dominantly cytoplasmic with some punctate fluorescent
Molecular Reproduction and Development. DOI 10.1002/mrd
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Fig. 1. mRNA transcripts encoding TRP53, PP2Cd, and CDKN2A
in 1-cell (1C), 2-cell (2C), 4-cell (4C), 8-cell (8C), morula (MOR), and
blastocyst (BL) stage embryos. Gel representative of three independent
developmental series depicting qualitative detection of transcripts
throughout mouse preimplantation development (A). Positive control
(Pos) is adult liver tissue, and negative control (Neg) is no transcript
added to the PCR reaction. To confirm identities of the PCR products,
samples of blastocyst PCR products were sequenced. B–D: Illustrate
quantitative real-timePCRanalysis of theTrp53,Ppm1d, andCdkn2a.
Values shown are normalized to exogenous luciferase added before
RNA extraction and set relative to the amount of the transcript of
interest in the 1-cell sample. Lowercase letters denote significant
differences (P0.05).
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foci appearing near the nuclei in each blastomere
(Fig. 2H–N). Although not a quantitative assay PP2Cd
immunofluorescence was consistently more intense at
the 1-, 2-, and 4-cell stages and lower at the 8-cell and
morula stages (Fig. 2H–L). Furthermore, the cytoplas-
mic immunofluorescence declined over these stages and
thepunctatefluorescent patternbecamemoredominant
by the morula stage (Fig. 2L). At the blastocyst stage,
PP2Cd immunofluorescence was barely detectable in
both trophectoderm and inner cell mass cell lineages
(Fig. 2M).
Effects ofMAPK14/11 Inhibition onDevelopment,
and Trp53, Ppm1d, Cdkn2a, and
Mapk14 mRNA Levels
Our primary hypothesis states that p38 MAPK
regulates Trp53, Ppm1d, and Cdkn2a and its own
transcript levels during preimplantation development.
To test this hypothesis, 2-cell and 8-cell embryos were
flushed and cultured in KSOMaa medium plus 0.1%
DMSO, KSOMaa medium plus 10 mM SB202474
(inactive CSAID analog), or KSOMaa medium plus
10 mMSB220025 (activeCSAID) for 12 and 24hr prior to
assessment of outcomes that included observing effects
on embryo development and measuring effects on
Trp53, Ppm1d, Cdkn2a, and Mapk14 mRNA levels by
the application of real-time RT-PCR methods. Three
independent trials were completed. We applied treat-
ments to both 2-cell and 8-cell stage embryos to replicate
the experimental design used in our earlier studies
(Natale et al., 2004; Paliga et al., 2005) investigating
effects of CSAID treatment on mouse preimplantation
development. By using the same stages and experi-
mental design we have maintained a consistent design
across studies to increase our overall understanding of
p38 MAPK function during preimplantation develop-
ment.
Treatment with SB220025 did not significantly affect
(P0.05) development of 2-cell stage embryos at either
the 12 or 24 hr time points (data not shown). However,
Trp53 mRNA levels were significantly (P 0.05) ele-
vated (10 and 150% increases, respectively) over control
levels (DMSO and SB202474 treatment) following 12
and 24 hr treatment with SB220025 (Fig. 3A,B). Ppm1d
mRNA levels displayed a more rapid increase than
Trp53 mRNAs as Ppm1d mRNAs were significantly
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Fig. 2. Localization of TRP-Phospho and PP2Cd polypeptides
during mouse preimplantation development. 1-cell (A,H), 2-cell (B,I),
4-cell (C,J), 8-cell (D,K), morula (E,L), and blastocyst (F, M) stage
embryoswere flushed at timed stages of development and processed for
application of indirect immunofluorescence methods for the detection
of TRP53-phospho (A–G) and PP2Cd (H–N) polypeptides. Three
independent replications were completed and 8–10 embryos of each
stage were examined per replication. Panels G and N depict the
negative controls. Protein of interest in represented in green and red
indicates rhodamine phalloidin.
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Fig. 3. Variations in Trp53 (A,B), Ppm1d (C,D), Cdkn2a (E,F), and Mapk14 (G,H) mRNA levels
following 12 and 24 hr CSAID treatment of 2-cell embryos. 2-cell embryos were collected and treated for
12 hr (A,C,E,G) and 24 hr (B,D,F,H) in 0.1% dimethylsulphoxide (DMSO), 10 mM SB202474 (inactive
CSAID, 474), and 10 mMSB220025 (activeCSAID, 025) prior to application of Real-TimeRT-PCRmethods.
mRNA values were normalized to exogenous luciferase mRNA and set relative to control DMSO cultured
embryos. Error bars are SE. Lowercase letters denote statistically significant differences (P0.05).
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(P 0.05) elevated (130 and 160%, respectively) over
control levels following both 12 and 24 hr treatment
with SB220025 (Fig. 3C,D). In contrast to these results
Cdkn2a mRNA levels did not display a significant
increase over that of control levels following 12 hr
treatment with SB220025 (Fig. 3E,F), however by 24 hr
of treatment Cdkn2a mRNA levels were significantly
(P 0.05) higher (180% increase) in the SB220025
treatment group over that observed for controls
(Fig. 3E,F). Mapk14 transcripts were also significantly
elevated following treatment with 10 mM SB220025 for
12 and 24 hr (Fig. 3G,H). However, in contrast to the
other genes of interest, Mapk14 mRNAs displayed a
maximal elevation compared to control levels following
12 hr of treatment with SB220025 (140% increase over
controls) (Fig. 3G). By 24hr of treatmentwith SB220025
Mapk14 levels were still significantly (P 0.05) higher
than that of controls but the fold difference between
groups was much lower than that observed following
12hrofSB220025 treatment (70% increase over controls
Fig. 3H).
In contrast to results following treatment of 2-cell
stage embryos with SB220025, the majority of 8-cell
stage embryos treated with 10 mM SB220025 for 12 hr
remained at the 8-cell stage (68%), while most of the
embryos in control groups compacted (65%) (data not
shown).After 24hr ofCSAID treatment, the variation in
development was even more striking, with only 5% of
8-cell embryos placed in the 10 mMSB220025 treatment
group progressing to the blastocyst stage, compared to
43–48% of the embryos placed into the control groups
(data not shown). These results have replicated out-
comes reported in Natale et al. (2004) and demonstrate
the consistency of our experimental design and the
treatment effects of SB220025 on preimplantation
development. As observed following the treatment of
2-cell stage embryos, Trp53 and Ppm1d mRNAs were
significantly (P0.05) elevated above control levels
following 12 and 24 hr treatment of 8-cell embryos in
10 mM SB220025 (60 and 50% above control levels for
Trp53, and 60 and 40% above control levels for Ppm1d;
Fig. 4A–D). However, in contrast to the 2-cell experi-
mental results, Cdkn2amRNA levels increased signifi-
cantly (P 0.05) by 140% over the control levels after a
12 hr treatment of 8-cell embryos in 10 mM SB220025,
but decreased significantly (P0.05) to become 60% of
control levels by 24 hr of CSAID treatment (Fig. 4E,F).
Mapk14 mRNA levels did not vary significantly among
treatment groups following 12 hr of CSAID treatment,
but theywere observed to decline significantly (P0.05)
to become 50% of control levels following 24 hr of
treatment in 10 mM SB220025 (Fig. 4G,H). In total our
results indicate that Trp53, Ppm1d, Cdkn2a, and
Mapk14 transcripts are affected by p38 MAPK inhibi-
tion during preimplantation development and that
these effects vary across embryo stages.
DISCUSSION
This study has characterized the expression ofTrp53,
Ppm1d, and Cdkn2a gene products during mouse
preimplantation development. Using a pharmacological
inhibitor of p38MAPKa/b-MAPK14/11, we have demon-
strated that Trp53, Ppm1d, Cdkn2a, and Mapk14
mRNA levels are affected by p38 MAPK inhibition and
that outcomes following p38 MAPK inhibition on
Cdkn2a and Mapk14 mRNAs vary between the 2-cell
and the 8-cell embryo stages. This work serves to
increase our understanding of the molecular signaling
pathways that regulate and assist in responding to
stressful conditions that preimplantation embryos face
in culture.
Recent research is focused on defining the specific
cellular pathways that regulate stress responses in the
early embryo, to understandhow the early embryo copes
with and responds to the culture environment. This
research has revealed that MAPK signaling pathways
are important mediators of environmental stress influ-
ences on embryonic gene expression and development
(Saba-El-Leil et al., 2003; Natale et al., 2004; Maekawa
et al., 2005; Paliga et al., 2005; Wang et al., 2005).
Interestingly, Natale et al. (2004), discovered that
inhibition of MAPK14/11 activity by employing CSAID
treatment, results in a reversible arrest of preimplanta-
tion development at the 8–16 cell stage in the mouse.
Importantly, treated embryos recovered completely
from p38 MAPK blockade and proceeded to the blas-
tocyst stage at the same frequency as controls, however,
this recovery was delayed by the same time period in
which the embryos were exposed to CSAID treatment
(Natale et al., 2004).
The present study was directed at expanding our
understanding of p38 MAPK function and regulation
during preimplantation development by characterizing
the expression and responsiveness of p38 MAPK
targets, Trp53, Ppm1d, and Cdkn2a during preimplan-
tation development (Bulavin et al., 1999; Sanchez-
Prieto et al., 2000; Takekawa et al., 2000). Studies have
indicated that p38 MAPK directly phosphorylates and
activates TRP53 (Kishi et al., 2001). TRP53 in turn
upregulates the expression of the protein phosphatase
PP2Cd. PP2Cd has been recently characterized as an
endogenous protein phosphatase inhibitor of p38MAPK
as it selectively dephosphorylates p38 MAPK on
threonine 180 (Takekawa et al., 2000). In the absence
of PP2Cd, p38 MAPK activity increases, as well as the
expression of Trp53 Cdkn2a, an upstream regulator of
retinoblastoma (RB) protein (Bulavin et al., 2004).
The first objective was to determine the developmen-
tal expression profiles of Trp53 and Ppm1dmRNAs and
proteins and Cdkn2amRNAs throughout preimplanta-
tion development. Qualitative reverse-transcription
PCR, quantitative real-time RT-PCR and whole-mount
immunofluorescence methods with confocal microscopy
were employed to determine that mRNAs encoding all
three of these genes of interest and phospho-TRP53 and
PP2Cd polypeptides were present throughout mouse
preimplantationdevelopment.Trp53mRNAlevelswere
high at the 1-cell stage, dropped significantly at the 2-
cell stage, then rose steadily from the 8-cell stage to the
blastocyst stage. These results are in close agreement
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Fig. 4. Variations in Trp53 (A,B), Ppm1d (C,D), Cdkn2a (E,F), and Mapk14 (G,H) mRNA levels
following 12 and 24 hr CSAID treatment of 8-cell embryos. 8-cell embryos were collected and treated for
12 hr (A,C,E,G) and 24 hr (B,D,F,H) in 0.1% dimethylsulphoxide (DMSO), 10 mM SB202474 (inactive
CSAID, 474), and 10 mMSB220025 (activeCSAID, 025) prior to application of Real-TimeRT-PCRmethods.
mRNA values were normalized to exogenous luciferase mRNA and set relative to control DMSO cultured
embryos. Error bars are SE. Lowercase letters denote statistically significant differences (P0.05).
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with (Jurisicova et al., 1998) who reported Trp53 levels
in CD-1 and C57BL/6 mouse embryos at 18, 49, 57, 67,
88, and 97 hr post-hCG using quantitative dot blot
hybridization. This pattern of mRNA accumulation is
commonly reported for transcripts during mouse pre-
implantation development and likely demonstrates the
turnover of large pools of maternal transcripts in the 1-
cell stage that become degraded at the 2-cell stage prior
to replacement via activation of zygote genome tran-
scriptional activity and accumulation of gene tran-
scripts through development to the blastocyst stage
(Nothias et al., 1995; Hamatani et al., 2004; Alizadeh
et al., 2005). The main variation that TRP53 mRNAs
displayed from this pattern is that their reaccumulation
following the 2-cell low did not begin immediately and
was delayed until the 8-cell stage. Phosphorylated
TRP53 protein was detected in all preimplantation
embryo stages primarily confined to the cytoplasm,
however, phosphor-TRP53 immunolocalization was
detected in the nuclei in a few blastomeres beginning
at the 4-cell stage and continuing to the blastocyst stage.
Studies have determined that TRP53’s cellular localiza-
tion is tightly linked to the cell cycle (Liang and Clarke,
2001; O’Brate and Giannakakou, 2003; Lavin and
Gueven, 2006). TRP53 accumulates in the cytoplasm
during the G1 phase and enters the nucleus during the
G1/S phase transition (Liang and Clarke, 2001). A short
period after the beginning of S phase, TRP53 cycles back
to the cytoplasm (Liang and Clarke, 2001). Since cell
division in cleavage stage embryos is asynchronous, one
would not expect all of the blastomeres to be at the same
phase of the cell cycle. The presence of nuclear phospho-
TRP53 beginning at the 4-cell stage then may simply
reflect this asynchronous nature of the cleavage divi-
sions during preimplantation development and also
indicates the proportion of the blastomeres at each
embryonic stage that are engaged in the G1/S phase of
the cell cycle.
Ppm1d and Cdkn2a both displayed a very different
pattern of mRNA accumulation during preimplantation
development from that observed for Trp53 transcripts,
which consisted of high levels at the 1-cell stage that
dropped at the 2-cell stage and remained low but
detectable through to the blastocyst stage. This pattern
of mRNA accumulation could represent a sustained
oogenetic transcript pattern in which the maternal
transcripts are stabilized through development to the
blastocyst stage. Alternatively it may reflect very low
but sustained transcription of these gene products by
the embryonic genome following the degradation of
maternal transcripts during the 1- to 2-cell transition.
The unusual accumulation profile displayed by Ppm1d
and Cdkn2a mRNAs has been observed by others for
additional genes including stat3, N-cadherin, and rac1
(Hamatani et al., 2004).
PP2Cd protein was detected in all preimplantation
stages by the application of immunofluorescence meth-
ods. PP2Cdfluorescencewas primarily cytoplasmicwith
punctate fluorescent foci accumulating near the nucleus
in each blastomere. Overall a qualitative assessment of
PP2Cdfluorescence indicated that therewas a reduction
in PP2Cd fluorescence from the 8-cell stage onward.
By the blastocyst stage, PP2Cd fluorescence was only
faintly detectable. These data correspond well with the
mRNA expression pattern of PP2Cd. It is intriguing
to report that PP2Cd protein expression appears
to decrease as a developmental dependence on p38
MAPKa/bemergesat the8- to 16-cell stage (Natale et al.,
2004; Paliga et al., 2005). It is possible that PP2Cd is
primarily a regulator of p38 MAPK during the early
cleavage stages prior to when p38 MAPKa/b activity is
absolutely required for normal developmental progres-
sion.
In a pioneering paper on the structure and expression
of PP2Cd, (Choi et al., 2000) reported PP2Cd expression
in embryo stages from E8.5 to E19 and also demon-
strated that its expression was ubiquitous in all adult
tissues suggesting a role in basic cellular functions
shared by all cells. Although the physiological role of
PP2Cd in cell cycle control is not fully understood, it has
been suggested that PP2Cd regulates the TRP53-
induced growth arrest response. By dephosphorylating
critical target proteins such as p38 MAPK and uracil
DNA glycosylase 2 (UNG2), an important base excision
repair protein, PP2Cd may enhance the cell-cycle
inhibitory activities of its targets or it may contribute
to a regulatory feedback mechanism that acts to reduce
cell-cycle inhibitory activity following an initial activa-
tion period. In conjuction with the TRP53 results, the
presence of both phosphorylated TRP53 and PP2Cd
suggests that the regulatory negative feedbackmechan-
ism for p38 MAPK could be active in mouse preimplan-
tation embryos.
Interestingly, it has been previously reported that
Cdkn2a is not expressed duringmouse development and
that transcripts for this gene only appear following birth
(Zindy et al., 1997). However, Zindy et al. (1997)
employed Northern Blot analysis and only examined
expression from days 7 to 17 of embryogenesis, far after
the preimplantation stages that we investigated in the
present study. It is possible that Cdkn2a transcript
levels continue todrop off further into developmentafter
the blastocyst stage to a point where they are undetect-
able. In fact, Cdkn2a-null animals develop normally
(Serrano et al., 1996). Zindy et al. (1997) showed that
Cdkn2a expression is low throughout early postnatal
life, and rises asmice age suggesting a role forCdkn2a in
cell senescence. The most likely reason for the discre-
pancy between studies is thatwe employed amuchmore
sensitive method of transcript analysis and it is
conceivable that the low but steady levels of Cdkn2a
mRNA thatwe detected using real-timeRT-PCRare not
contributing an indispensable role during preimplanta-
tion development. Regardless, we did not investigate
CDKN2A protein distribution due to its low mRNA
expression after the 1-cell stage.
The main hypothesis of our study is that p38 MAPK
regulates Trp53, Ppm1d, Cdkn2a, and possibly its own
transcript levels during preimplantation development.
To test this hypothesis, 2-cell and 8-cell embryos were
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cultured in 0.1% DMSO (control), 10 mM SB202474
(inactiveCSAID), or 10mMSB220025 (activeCSAID) for
12 and 24 hr then assessed for morphology prior to the
application of real-time RT-PCR methods to contrast
treatment effects on Trp53, Ppm1d, Cdkn2a, and p38
mapka mRNA levels. No significant effects to develop-
ment of 2-cell stage embryos were observed at 12 or
24 hr. Treatment of 8-cell embryos did result in arrested
development at the 8-cell to 16-cell stages at 12 and
24 hr. These results are in complete agreement with the
findings reported inNatale et al. (2004) and Paliga et al.
(2005). These studies reported that a CSAID concentra-
tion as low as 2 mMSB220025was sufficient to eliminate
phospho-MAPKAPK-2 (a direct downstream target of
activated p38 MAPK) immunostaining (Natale et al.,
2004; Paliga et al., 2005). However, this low dose only
resulted in a reduced developmental delay. The 10 mM
SB220025 concentration employed in the present study
wasan intermediate level between the2mMdoseand the
20mMdoseutilized in these earlier studies (Natale et al.,
2004; Paliga et al., 2005).
One of the most intriguing outcomes from the present
study is the variation in stage-specific effects of CSAID
treatment on Trp53, Ppm1d, Cdkn2a, and Mapk14
mRNA levels. Since p38 MAPKa/b activity is required
for development past the 8- to 16-cell stage it is possible
that the mechanisms used to regulate the activity of
this MAPK pathway vary between the 2-cell and 8-cell
stages of development. Trp53 and Ppm1d mRNAs may
be regulated similarly at the 2-cell and 8-cell stages as
they were both elevated following CSAID treatment at
both time points in 2-cell and 8-cell embryos. These
results do not agree with the negative feedback model
proposed by Bernards (2004) where p38 MAPK is
predicted to activate TRP53, which in turn activates
PP2Cd, to downregulate p38MAPKactivity.Our results
raise the possibility that this pathway and the propos-
ed interactions of p38 MAPK, TRP53, PP2Cd, and
CDKN2A do not occur in the early embryo as has been
reported for established cell lines (Bernards, 2004).
Instead the results suggest that p38 MAPKa/b inhibi-
tion for 12 and 24 hr is associated with upregulation
of Trp53 mRNA levels which are also associated
with increased Ppm1d mRNA levels. The regulation of
Ppm1d mRNA levels in conjunction with elevated
TRP53 expression is consistentwith the proposedmodel
(Bernards, 2004). Recently Fabian et al. (2006) reported
that ERK is transiently activated following p38 MAPK
inhibition inPC12 cell lines (rat adrenal tumor) and this
is associated with increased TRP53 protein and mRNA.
However, cautionmust be exercisedwhen attempting to
correlate outcomes between post-translational activa-
tion of proteins and mRNA abundance.
Cdkn2a mRNA was elevated over controls following
treatment of 2-cell embryos for 24 hr. It was also
elevated following treatment of 8-cell embryos for
12 hr, but below control levels after 24 hr. These results
suggest that Cdkn2a mRNA is differentially regulated
at the 8-cell stage in response to decreased p38MAPKa/
b activity. In the absence of active p38 MAPKa/b at the
8-cell stage, Cdkn2a levels may at first rise in an
response to CSAID treatment, however this is not
maintained, and its levels decline. The 2-cell stage
embryo, however, maintains these elevated Cdkn2a
levels. Another reasonable possibility is that since
Cdkn2a is expressed at such a low levels in preimplan-
tation embryos, and Cdkn2a-null mice exhibit normal
prenatal development, the observed differences in
Cdkn2a mRNA expression simply have little conse-
quence to early development (Serrano et al., 1996).
The final important outcome from this study is that
Mapk14 mRNA expression is regulated by blocking
MAPK 14/11 activity, andMapk14mRNAwas differen-
tially regulated at the 2-cell and 8-cell stages following
CSAID treatment. At the 2-cell stage, inhibition of
MAPK14/11 activity was linked with elevated levels of
Mapk14mRNAs after 12 and 24 hr of CSAID treatment.
In contrast, at the 8-cell stage, after 12 hr in CSAID
treatment, Mapk14 mRNA levels did not differ signifi-
cantly from controls, but was significantly decreased
from control levels after 24 hr of CSAID treatment.
These results indicate that at the 2-cell stage Mapk14
gene expression is responsive to changes inMAPK14/11
activity. Thus, at the 2-cell and 4-cell stages it may be
possible to compensate for reducedMAPK14/11 activity
by increasing Mapk14 expression. At the 8-cell stage
thismechanism does not assert itself to the same degree
as Mapk14 levels do not increase and in fact decline in
the presence of MAPK 14/11 inhibitors. This result is
especially intriguing as this stage also represents the
time of first developmental sensitivity to CSAID treat-
ment. Perhaps this arises due to an inability of the
embryo at this stage to maintain required Mapk14
transcript levels in the presence of the inhibitor. These
studies certainly support the vulnerability of 8- to
16-cell stage embryos to CSAID treatment which has
now been associated with reduced Mapk14 transcript
levels in addition to loss of filamentous actin (Paliga
et al., 2005). Why Mapk14 gene expression displays a
greater dependence on p38 MAPK activity at the 8-cell
stage is unknown at this time but this discovery
certainly represents an important avenue for further
experimentation in the future.
In conclusion, p38 MAPKs regulate many important
cellular functions such as inflammation, cell prolifera-
tion, and apoptosis in several different cellular systems
(Enslen et al., 2000; Ono and Han, 2000; Kyriakis and
Avruch, 2001). This study has characterized the expres-
sion ofTrp53,Ppm1d, andCdkn2ageneproducts during
preimplantation development. This is the first study to
show the presence of PP2Cd gene products in preim-
plantation embryos. As a predicted endogenous inhibi-
tor of p38 MAPK activity, it is interesting to discover
that PP2Cdprotein expressionmay decrease around the
8-cell stage, when p38 MAPK activity is absolutely
required for developmental progression. As well,
this study demonstrated a stage-specific regulation of
Cdkn2a andMapk14mRNA expression following treat-
ment of 2-cell and 8-cell embryos for 12 and 24 hr with
the MAPK 14/11 inhibitor, SB220025.
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